Ernexa Therapeutics Inc.ERNA
Price (close)
$3.45
Market cap
$5.6M
P/E
—
Revenue (TTM)
—
Net income
-$12.3M
Dividend yield
—
1-year total return
-87.7%
Net margin
—
Revenue growth
—
Debt / equity
—
What Ernexa Therapeutics Inc. does.
are a preclinical-stage synthetic allogeneic iMSC therapy company. iMSCs are induced pluripotent stem cell (“iPSC”)-derived
mesenchymal stem cells. We envision a future where cell therapies powered by synthetic iMSCs can offer new options for patients with
limited treatment paths and our mission is to transform the treatment of cancer and autoimmune disease by developing scalable, affordable,
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $5.8M | — | $0 | $68,000 | $582,000 | — |
| Net income | -$7.3M | -$122.5M | -$24.6M | -$21.7M | -$44.5M | -$14.1M |
| Free cash flow | -$8.1M | -$23.6M | -$21.3M | -$20.4M | -$16.2M | -$7.1M |
More on ERNA.
- Ernexa Therapeutics Inc. summary
- Ernexa Therapeutics Inc. financial statements
- Ernexa Therapeutics Inc. key metrics
- Ernexa Therapeutics Inc. health scores and style box
- Ernexa Therapeutics Inc. earnings
- Ernexa Therapeutics Inc. dividends
- Ernexa Therapeutics Inc. valuation
- Ernexa Therapeutics Inc. ownership and insiders
- Ernexa Therapeutics Inc. peers
Figures from Ernexa Therapeutics Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.